Public Views of Gene Editing for Babies Depend on How It Would Be Used
By Cary Funk and Meg Hefferon,
Pew Research Center
| 07. 26. 2018
Americans’ views on the appropriateness of changing a baby’s genetic characteristics depend in large part on the intended purpose and on whether or not human embryos would be used in testing these techniques. A majority of Americans support the idea of using gene editing with the goal of delivering direct health benefits for babies, but at the same time, a majority considers the use of such techniques to boost a baby’s intelligence something that takes technology “too far.”
About seven-in-ten Americans (72%) say that changing an unborn baby’s genetic characteristics to treat a serious disease or condition that the baby would have at birth is an appropriate use of medical technology, while 27% say this would be taking technology too far. A somewhat smaller share of Americans say gene editing to reduce a baby’s risk of developing a serious disease or condition over their lifetime is appropriate (60% say this, while 38% say it would be taking medical technology too far). But just 19% of Americans say it would be appropriate to use gene editing to make a baby more...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...